Detalhe da pesquisa
1.
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
Lancet
; 399(10337): 1779-1789, 2022 05 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35378077
2.
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
J Infect Dis
; 225(10): 1741-1749, 2022 05 16.
Artigo
Inglês
| MEDLINE | ID: mdl-35301540